Actionable mutations panel
Actionable mutations in solid tumors
Until recently, tumor genetic analysis was performed in the context of each organ and sequentially, which implied a higher cost and longer time to obtain the results, as well as the need to have enough tumor tissue to perform all the different studies.
The new technologies of massive sequencing allow the simultaneous analysis of a large number of alterations, thus allowing identifying the genetic characteristics of the tumor, consequently facilitating the application of a personalized treatment for each patient. This new technology improves the cost-effectiveness of the diagnosis, as well as considerably reducesthe time to obtain the results. In addition, each cancer is unique, so the analysis of actionable mutations in solid tumors provides the oncologist with relevant information to treat the patient in a more precise and personalized way.
The Actionable Panel analyses 773 changes in 12 genes of clinical relevance in the treatment of solid tumors: KRAS, NRAS, KIT, BRAF, PDGFRA, ALK, EGFR, ERRB2, ERRB3, PIK3CA, ESR1 and RAF1.
The Actionable Panel was validated to detect single nucleotide variations (SNVs) as well as small insertions and deletions (<20pb) in specific regions of 12 genes from paraffin-embedded tumor-extracted DNA. This means that it is not necessary to retake a biopsy and that the archived samples can be analyzed, and it is advisable to always use the latest one.
The test indicated for patients with any type of solid tumor:
• Patients who were not subject to a genetic analysis of the tumor.
• Patients with negative results for mutations in certain genes and in which they want to complete the analysis studying other genes included in the panel.
• Patients who wish to optimize the available material and the time of obtaining the results.
• Patients who exhausted all possibilities of clinical treatment.
Consequently, the Actionable Panel is an extremely useful tool in customizing the solid tumor treatment plan.
• The test is not recommended in cases of haematological malignancies.
Multiplex PCR, algorithm and sequencing
• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Any pathogenic mutation or mutation of uncertain significance is confirmed from a new DNA extraction followed by Sanger sequencing that guarantees 100% coverage of all DNA-readable bases.
DOCUMENTATION – Available on Extranet for clients:
• Informed Consent
• Clinical Questionnaire
• Fasting is not necessary for the test.